This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Thursday, April 23, 2015
Merck and Gilead square off in battle of the next-next-gen hep C combos
Early today both Gilead and Merck issued new data on their next-next-gen hepatitis C combos, demonstrating just how brutal the competition for market share is becoming while highlighting some of the boundaries that are emerging in shortening treatment regimens.
In a late-breaker at the annual meeting of the European Association for the Study of the Liver in Vienna, Gilead investigators highlighted a sustained response for the triple of 93% among treatment-naïve noncirrhotic patients after 6 weeks of therapy. That figure dropped to 87% for cirrhotic patients and 67% for treatment-resistant patients. The 4-week SVR rate simply failed with a 27% response rate, which will likely bar Gilead's combo from joining any fast-acting therapies that may eventually compete for this category.
No comments:
Post a Comment